These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11935377)

  • 21. The neuropeptides VIP/PACAP and T cells: inhibitors or activators?
    Ganea D; Delgado M
    Curr Pharm Des; 2003; 9(12):997-1004. PubMed ID: 12678866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vasoactive intestinal peptide (VIP) inhibits TGF-beta1 production in murine macrophages.
    Sun W; Tadmori I; Yang L; Delgado M; Ganea D
    J Neuroimmunol; 2000 Jul; 107(1):88-99. PubMed ID: 10808055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6.
    Delgado M; Martinez C; Pozo D; Calvo JR; Leceta J; Ganea D; Gomariz RP
    J Immunol; 1999 Jan; 162(2):1200-5. PubMed ID: 9916753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression.
    Delgado M; Sun W; Leceta J; Ganea D
    J Immunol; 1999 Oct; 163(8):4213-23. PubMed ID: 10510358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: players in innate and adaptive immunity.
    Ganea D; Rodriguez R; Delgado M
    Cell Mol Biol (Noisy-le-grand); 2003 Mar; 49(2):127-42. PubMed ID: 12887096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in LPS-stimulated macrophages.
    Delgado M; Ganea D
    J Neuroimmunol; 2000 Oct; 110(1-2):97-105. PubMed ID: 11024538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells.
    Cai Y; Xin X; Shim GJ; Mokuno Y; Uehara H; Yamada T; Agui T; Matsumoto K
    Endocrinology; 1997 Jun; 138(6):2515-20. PubMed ID: 9165043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemokine release is associated with the protective action of PACAP-38 against HIV envelope protein neurotoxicity.
    Brenneman DE; Hauser JM; Spong C; Phillips TM
    Neuropeptides; 2002 Aug; 36(4):271-80. PubMed ID: 12372701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression.
    Delgado M; Leceta J; Gomariz RP; Ganea D
    J Immunol; 1999 Oct; 163(7):3629-35. PubMed ID: 10490956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroprotective potential of three neuropeptides PACAP, VIP and PHI.
    Dejda A; Sokołowska P; Nowak JZ
    Pharmacol Rep; 2005; 57(3):307-20. PubMed ID: 15985713
    [TBL] [Abstract][Full Text] [Related]  

  • 31. VIP1 and VIP2 receptors but not PVR1 mediate the effect of VIP/PACAP on cytokine production in T lymphocytes.
    Jiang X; Wang HY; Yu J; Ganea D
    Ann N Y Acad Sci; 1998 Dec; 865():397-407. PubMed ID: 9928038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit CBP-NF-kappaB interaction in activated microglia.
    Delgado M
    Biochem Biophys Res Commun; 2002 Oct; 297(5):1181-5. PubMed ID: 12372411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. VIP and PACAP enhance IL-6 release and mRNA levels in resting peritoneal macrophages: in vitro and in vivo studies.
    Martinez C; Delgado M; Pozo D; Leceta J; Calvo JR; Ganea D; Gomariz RP
    J Neuroimmunol; 1998 May; 85(2):155-67. PubMed ID: 9630164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
    Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
    Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in endotoxin-activated microglia.
    Delgado M
    Biochem Biophys Res Commun; 2002 May; 293(2):771-6. PubMed ID: 12054537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression.
    Delgado M; Ganea D
    J Immunol; 2000 Jul; 165(1):114-23. PubMed ID: 10861043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuropeptides as modulators of macrophage functions. Regulation of cytokine production and antigen presentation by VIP and PACAP.
    Ganea D; Delgado M
    Arch Immunol Ther Exp (Warsz); 2001; 49(2):101-10. PubMed ID: 11348014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pituitary adenylate cyclase-activating polypeptide, helospectin, and vasoactive intestinal polypeptide in human corpus cavernosum.
    Hedlund P; Alm P; Ekström P; Fahrenkrug J; Hannibal J; Hedlund H; Larsson B; Andersson KE
    Br J Pharmacol; 1995 Oct; 116(4):2258-66. PubMed ID: 8564257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide inhibit dendritic growth in cultured sympathetic neurons.
    Drahushuk K; Connell TD; Higgins D
    J Neurosci; 2002 Aug; 22(15):6560-9. PubMed ID: 12151535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
    Akesson L; Ahrén B; Edgren G; Degerman E
    Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.